Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 11, 2008. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction notification rather than general financial performance.
Material Changes
The filing details a re-valuation of the cash element of a notional investment held within the US Retirement Savings Plan. This resulted in an increase in the notional allocation of Ordinary share ADRs on April 4, 2008, at a price of $45.33 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: April 4, 2008.
- Notification Date: April 11, 2008.
- Instrument: GSK Ordinary share ADRs.
- Transaction Price: $45.33 per ADR.
- Involved Party: S M Werner (Director/Managerial Responsibility).
- Context: Increase in notional allocation due to plan re-valuation.